OBJECTIVE: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy; however, this has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after radical prostatectomy. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumour samples and the risk of BCR after SRT. METHODS: 109 males who were treated with SRT were included. The percentage of cells with nuclear staining and GATA2 staining intensity were both measured. These two measures were multiplied together to obtain a GATA2 H-score (range 0-12) which was our primary GATA2 staining measure. RESULTS: In unadjusted analysis, the risk of BCR was higher for patients with a GATA2 H-score >4 (hazard ratio = 2.04, p = 0.033). In multivariable analysis adjusting for SRT dose, pre-SRT PSA, pathological tumour stage and Gleason score, this association weakened substantially (hazard ratio = 1.45, p = 0.31). This lack of an independent association with BCR appears to be the result of correlations between GATA2 H-score >4 and higher pre-SRT PSA (p = 0.021), higher Gleason score (p = 0.044) and more severe pathological tumour stage (p = 0.068). CONCLUSION: Higher levels of GATA2 expression appear to be a marker of prostate cancer severity; however, these do not provide independent prognostic information regarding BCR beyond that of validated clinicopathological risk factors. Advances in knowledge: A higher GATA2 expression level appears to be correlated with known measures of prostate cancer severity and therefore is likely not an independent marker of outcome after SRT.
OBJECTIVE: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy; however, this has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after radical prostatectomy. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumour samples and the risk of BCR after SRT. METHODS: 109 males who were treated with SRT were included. The percentage of cells with nuclear staining and GATA2 staining intensity were both measured. These two measures were multiplied together to obtain a GATA2 H-score (range 0-12) which was our primary GATA2 staining measure. RESULTS: In unadjusted analysis, the risk of BCR was higher for patients with a GATA2 H-score >4 (hazard ratio = 2.04, p = 0.033). In multivariable analysis adjusting for SRT dose, pre-SRT PSA, pathological tumour stage and Gleason score, this association weakened substantially (hazard ratio = 1.45, p = 0.31). This lack of an independent association with BCR appears to be the result of correlations between GATA2 H-score >4 and higher pre-SRT PSA (p = 0.021), higher Gleason score (p = 0.044) and more severe pathological tumour stage (p = 0.068). CONCLUSION: Higher levels of GATA2 expression appear to be a marker of prostate cancer severity; however, these do not provide independent prognostic information regarding BCR beyond that of validated clinicopathological risk factors. Advances in knowledge: A higher GATA2 expression level appears to be correlated with known measures of prostate cancer severity and therefore is likely not an independent marker of outcome after SRT.
Authors: Alexander S Parker; Michael G Heckman; Yuri Sheinin; Kevin J Wu; Tracy W Hilton; Nancy N Diehl; Thomas M Pisansky; Steven E Schild; Eugene D Kwon; Steven J Buskirk Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-02 Impact factor: 7.038
Authors: Richard J Lee; Katherine S Tzou; Michael G Heckman; Corey J Hobbs; Bhupendra Rawal; Nancy N Diehl; Jennifer L Peterson; Nitesh N Paryani; Stephen J Ko; Larry C Daugherty; Laura A Vallow; William Wong; Steven Schild; Thomas M Pisansky; Steven J Buskirk Journal: BJU Int Date: 2015-08-22 Impact factor: 5.588
Authors: Y Zhou; K C Lim; K Onodera; S Takahashi; J Ohta; N Minegishi; F Y Tsai; S H Orkin; M Yamamoto; J D Engel Journal: EMBO J Date: 1998-11-16 Impact factor: 11.598
Authors: Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh Journal: JAMA Date: 2008-06-18 Impact factor: 56.272
Authors: Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown Journal: Cell Date: 2009-07-23 Impact factor: 41.582
Authors: Stephen J Freedland; Voleak Choeurng; Lauren Howard; Amanda De Hoedt; Marguerite du Plessis; Kasra Yousefi; Lucia L Lam; Christine Buerki; Seong Ra; Bruce Robbins; Edouard J Trabulsi; Nikhil L Shah; Firas Abdollah; Felix Y Feng; Elai Davicioni; Adam P Dicker; Robert J Karnes; Robert B Den Journal: Eur Urol Date: 2016-01-21 Impact factor: 20.096
Authors: Alexander S Parker; Michael G Heckman; Kevin J Wu; Julia E Crook; Tracy W Hilton; Thomas M Pisansky; Johnny R Bernard; Steven E Schild; Li Yan Khor; Elizabeth H Hammond; Alan Pollack; Steven J Buskirk Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-21 Impact factor: 7.038
Authors: Yan Ting Chiang; Kendric Wang; Ladan Fazli; Robert Z Qi; Martin E Gleave; Colin C Collins; Peter W Gout; Yuzhuo Wang Journal: Oncotarget Date: 2014-01-30
Authors: J Woo; S Santasusagna; J Banks; S Pastor-Lopez; K Yadav; M Carceles-Cordon; A Dominguez-Andres; R B Den; L R Languino; R Pippa; C D Lallas; G Lu-Yao; W K Kelly; K E Knudsen; V Rodriguez-Bravo; A K Tewari; J M Prats; B E Leiby; L G Gomella; Josep Domingo-Domenech Journal: J Urol Date: 2020-04-06 Impact factor: 7.450